capecitabine breast cancer

Release time ：Dec-25,2024

Capecitabine is a frequently utilized medication in the treatment of breast cancer, functioning by converting into 5-fluorouracil to suppress the proliferation of cancer cells. Generally, capecitabine exhibits some efficacy against breast cancer, although its effectiveness can vary among individuals.

During capecitabine therapy for breast cancer, side effects such as nausea, vomiting, diarrhea, and oral mucositis may arise. These side effects are typically mild and can be mitigated by adjusting the dosage or employing supportive medications. However, in rare instances, capecitabine can lead to severe adverse effects, including cardiac issues, hepatic impairment, and myelosuppression. Should these serious side effects occur, it is imperative to discontinue the medication immediately and seek medical assistance.

For breast cancer patients undergoing capecitabine treatment, it is advised to adhere to the physician's instructions, regularly undergo blood tests, and conduct other necessary examinations to monitor the medication's efficacy and side effects. Additionally, patients should maintain healthy lifestyle practices, including a balanced diet, moderate physical activity, and abstaining from smoking and alcohol consumption, to enhance treatment outcomes and overall quality of life. Patients should not discontinue or alter the dosage of capecitabine without consulting their healthcare provider, as this may compromise therapeutic efficacy or heighten the risk of side effects. Any concerns or discomforts should be promptly addressed by consulting a physician.